Verrica Pharmaceuticals Inc. Production Related Impairments or Charges
Verrica Pharmaceuticals Inc. (VRCA) reported Production Related Impairments or Charges of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProductionRelatedImpairmentsOrCharges · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. production related impairments or charges for the quarter ending 2025-12-31 was $100.00K.
- Verrica Pharmaceuticals Inc. production related impairments or charges for the quarter ending 2025-09-30 was $400.00K, a 100.00% increase year-over-year.
- Verrica Pharmaceuticals Inc. production related impairments or charges for the quarter ending 2024-09-30 was $200.00K.
- Verrica Pharmaceuticals Inc. production related impairments or charges for fiscal 2025 was $500.00K.
| Period end | Production Related Impairments or Charges 3 month | Production Related Impairments or Charges 6 month | Production Related Impairments or Charges 9 month | Production Related Impairments or Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $500.00K derived: sum of 2 quarters · filed 2026-03-11 | $500.00K 10-K · filed 2026-03-11 | |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-14 | $400.00K 10-Q · filed 2025-11-14 | ||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-14 | $600.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |